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Problem Identification
 Cigarette smoking is the leading cause of preventable death and disease 
in the United States, accounting for more than 480,000 deaths every year 
(1).
 The adult smoking prevalence in Franklin County, VT, in 2017 was 16.6%, 
approximately 1% higher than the national average (2,3).
 In 2017, there were 134 opioid-related overdose deaths in Vermont—a rate 
of 23.2 deaths per 100,000 persons and more than the national rate of 21.7
deaths per 100,000 persons (8).
 The prevalence of tobacco use among substance abuse treatment 
program enrollees has been shown to range between 75-97% (4,5).
Public Health Cost
 Smoking-related illness in the US costs more than $300 billion each 
year. This includes nearly $170 billion for direct medical care for 
adults and more than $156 billion in lost productivity (1,6).
 In Vermont, smoking costs the state approximately $348 million in 
medical expenses and results in about 1000 smoking-attributable 
deaths per year (7).
Community Perspective
 In order to gain a community
perspective on this issue, I 
spoke with Barbara Wynse, 
one of the clinic’s MAT 
coordinators, and an 
anonymous patient currently 
undergoing suboxone 
treatment at the clinic.
• “For many patients who are 
undergoing treatment for their 
opioid use disorder, quitting 
smoking is simply not as high of a 
priority as getting and staying 
sober.” – Barbara Wynes RN
• “It’s not that I don’t want to quit, 
but every time I try, the stress in my 
life drives me to pick it up again. 
Sometimes I feel like it’d be harder 




• A survey aimed at assessing quit attempt history, 
current motivation to quit, and barriers to quitting was 
developed and distributed to active smokers enrolled 
in the clinic’s suboxone treatment program.
• The “barriers” section of the survey is a modified version
of the BQS-SAT, a questionnaire originally developed 
and verified by Asher et al (9) with the purpose of 
assessing barriers to smoking cessation among patients in
substance abuse programs.
• Intervention
• A handout with information comparing and 
contrasting various quit aids and providing smoking 
cessation resources available to Vermont residents 





 Total # of responses: 14
 64.3% Male, 35.7% Female
 Average # of cigarettes/day: 12.07
 Average # of previous quit attempts: 3
 93% tried at least 1 quit aid/nicotine replacement
 Most commonly tried was the nicotine patch 
(78.6%)
 Motivation
 Average importance of making changes in smoking 
habits: 8.4/10
 Average confidence in ability to make changes: 
7.8/10




 Average # of barriers: 4.9
 Top 3 most common barriers: 
 1) “If I quit smoking, I would feel anxious” (85.7%)
 2) “When I don’t smoke, I feel restless and I can’t 
concentrate” (64.3%)
 3) “It’s hard to quit because so many others around me 
are smoking” (50%)
 3) “If I quit smoking, I would gain weight” (50%)
 Top 3 most “important” barriers:
 1) “If I quit smoking, my urges to use drugs will be so 
strong, I won’t be able to stand it” (4/5)
 2) “When I don’t’ smoke, I feel restless and I can’t 
concentrate” (3.78/5)
 3) “If I quit smoking, my urges to smoke will be so strong, I 





 The results of the survey provided Dr. Corrigan with useful 
information regarding the trends in motivation to quit and barriers 
to smoking cessation in his patient population. This information will 
allow him and his staff to target the most common and important 
barriers in their interventions and patient education.
 One way to evaluate the effectiveness of the handout would be 
to compare smoking rates, quit attempts, and quit aid use in the 
study population before receiving the handout and at certain 
time-points following the intervention (3, 6, 9 months).
 Limitations:
 Due to the time constraints of the clerkship, the sample size of the 
study population was not large enough to yield statistically 
significant results.
 Because the surveys were completed anonymously, only 
population data was gathered. This prevents Dr. Corrigan and his 
staff from using the survey responses to tailor patient-specific 
education and treatment plans.
Future 
Directions
 It would be useful to:
1. Continue to distribute this survey at Dr. Corrigan’s clinic in 
order to accumulate more responses and generate 
statistically significant data.
2. Perform a more in-depth statistical analysis comparing 
number and types of barriers with information collected on 
demographics, previous quit history, and motivation to 
change.
3. Distribute this survey and handout at other clinics in  Franklin 
county in order to obtain information that would be more 
generalizable to the rest of the county and provide an 
intervention to a broader patient population.
 It would be useful to use this survey as a tool for creating patient-
specific treatment plans, rather than as an anonymous data-
gathering instrument.
 An interesting future project could compare barriers to smoking 
cessation and motivation to quit in smokers enrolled in suboxone 
treatment programs with smokers who have concurrent opioid use 
disorder and are not enrolled in suboxone treatment programs.
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